Rami Yokoyama1, Masao Miyagawa2, Hideki Okayama3, Takeshi Inoue4, Hitoshi Miki4, Akiyoshi Ogimoto5, Jitsuo Higaki5, Teruhito Mochizuki2. 1. Department of Radiology, Ehime University Graduate School of Medicine, Japan. Electronic address: rami0528@m.ehime-u.ac.jp. 2. Department of Radiology, Ehime University Graduate School of Medicine, Japan. 3. Department of Cardiology, Ehime Prefectural Central Hospital, Japan. 4. Department of Radiology, Ehime Prefectural Central Hospital, Japan. 5. Department of Cardiology, Pulmonology, Hypertension & Nephrology, Ehime University Graduate School of Medicine, Japan.
Abstract
BACKGROUND: Imaging with fluorodeoxyglucose (FDG) PET/CT is used to diagnose patients with cardiac sarcoidosis (CS). However, its specificity is relatively low. We aimed to demonstrate that higher diagnostic specificity for CS can be obtained using quantitative methodology to analyze PET/CT. METHODS: A total of 125 consecutive patients with suspected CS were enrolled in the study. After clinical assessment and cardiac imaging studies, the patients underwent FDG PET/CT imaging after eating a low-carbohydrate diet followed by an overnight fast lasting ≥ 18 h. For visual analysis, fusion and maximum intensity projection images were reviewed. For quantitative analysis, the maximum standardized uptake value (SUV max) within the myocardium was obtained. RESULTS: Of the 92 patients who met study inclusion criteria, 37 were diagnosed with CS. Myocardial SUV max was significantly higher in patients with CS compared with non-CS patients (9.5 ± 4.8 vs. 3.0 ± 1.7, p < 0.0001). The area under the curve by receiver operating characteristic analysis was 0.960 for SUV max. Using a cut-off value of 4.0, the sensitivity was 97.3% and specificity was 83.6% for diagnosing CS, which is more accurate than visual analysis. Moreover, SUV max was the only significant predictor of CS among 10 clinical and imaging variables. In 18 patients who received steroid therapy with a mean follow-up duration of 6.4 ± 5.2 months, SUV max significantly decreased from 9.8 ± 4.2 to 5.5 ± 3.5 (p = 0.003). CONCLUSION: When evaluated by quantification of myocardial SUV max, FDG PET/CT imaging provides high sensitivity and specificity for diagnosing CS.
BACKGROUND: Imaging with fluorodeoxyglucose (FDG) PET/CT is used to diagnose patients with cardiac sarcoidosis (CS). However, its specificity is relatively low. We aimed to demonstrate that higher diagnostic specificity for CS can be obtained using quantitative methodology to analyze PET/CT. METHODS: A total of 125 consecutive patients with suspected CS were enrolled in the study. After clinical assessment and cardiac imaging studies, the patients underwent FDG PET/CT imaging after eating a low-carbohydrate diet followed by an overnight fast lasting ≥ 18 h. For visual analysis, fusion and maximum intensity projection images were reviewed. For quantitative analysis, the maximum standardized uptake value (SUV max) within the myocardium was obtained. RESULTS: Of the 92 patients who met study inclusion criteria, 37 were diagnosed with CS. Myocardial SUV max was significantly higher in patients with CS compared with non-CSpatients (9.5 ± 4.8 vs. 3.0 ± 1.7, p < 0.0001). The area under the curve by receiver operating characteristic analysis was 0.960 for SUV max. Using a cut-off value of 4.0, the sensitivity was 97.3% and specificity was 83.6% for diagnosing CS, which is more accurate than visual analysis. Moreover, SUV max was the only significant predictor of CS among 10 clinical and imaging variables. In 18 patients who received steroid therapy with a mean follow-up duration of 6.4 ± 5.2 months, SUV max significantly decreased from 9.8 ± 4.2 to 5.5 ± 3.5 (p = 0.003). CONCLUSION: When evaluated by quantification of myocardial SUV max, FDG PET/CT imaging provides high sensitivity and specificity for diagnosing CS.
Authors: Heikki Tuominen; Atte Haarala; Antti Tikkakoski; Pasi Korkola; Mika Kähönen; Kjell Nikus; Kalle Sipilä Journal: J Nucl Cardiol Date: 2017-06-05 Impact factor: 5.952
Authors: G Cameron Coleman; Peter W Shaw; Pelbreton C Balfour; Jorge A Gonzalez; Christopher M Kramer; Amit R Patel; Michael Salerno Journal: JACC Cardiovasc Imaging Date: 2016-07-20
Authors: Yan Yatsynovich; Damian Valencia; Mikhail Petrov; Juan David Linares; Mufti M Rahman; Nathaniel Dittoe Journal: Curr Treat Options Cardiovasc Med Date: 2018-08-07
Authors: Daniele Muser; Pasquale Santangeli; Simon A Castro; Jackson J Liang; Andres Enriquez; Thomas J Werner; Gaetano Nucifora; Silvia Magnani; Tatsuya Hayashi; Erica S Zado; Fermin C Garcia; David J Callans; Sanjay Dixit; Benoit Desjardins; Francis E Marchlinski; Abass Alavi Journal: Eur J Nucl Med Mol Imaging Date: 2018-04-02 Impact factor: 9.236